Postmastectomy Radiotherapy for Locally Advanced Breast Cancer Receiving Neoadjuvant Chemotherapy

Table 2

Locoregional recurrence, distant metastases, and overall survival rates according to clinical factors.

Variable	Patient	Overall survival		LRR free survival		DM free survival
		Deaths	𝑃 value	LRR	𝑃 value	DM	𝑃 value
Age groups
≤40	33	16		6		20
41–50	62	24		9		20
51–60	5	20		9		25
>60	25	12	0.73	2	0.74	13	0.67
Clinical T
T1	4	3		0		3
T2	52	15		3		18
T3	48	17		9		25
T4	66	37	0.09	14	0.28	40	0.12
Clinical N
N0	42	14		5		15
N1	95	39		11		49
N2	33	19	0.15	10	0.034	22	0.028
Clinical stage
IIA	16	5		0		5
IIB	51	17		6		21
IIIA	35	13		6		20
IIIB	63	36		14		39
IIIC	3	1	0.15	0	0.19	1	0.09
Multiple Foci
No	99	40		18		46
Yes	71	32	0.60	8	0.28	40	0.19
Downstage
No	115	50		19		64
Yes	55	22	0.34	7	0.31	22	0.029
PMRT
No	72	31		12		36
Yes	98	41	0.83	14	0.57	50	0.93
PMRT volumes
Chest wall	14	5		1		5
Chest wall + SC	74	34	0.35	12	0.38	43	0.11
NAC regimen
Anthracyclines-based	69	35		14		41
Anthracyclines- and taxanes-based	93	33		10		41
No anthracyclines	8	4	0.25	2	0.29	4	0.16
Adjuvant hormonal therapy
No	62	34		10		35
Tamoxifen	75	28		11		34
AIs	33	10	0.11	5	0.93	17	0.31
Total	170	72		26		86

LRR: locoregional recurrence; DM: distant metastases; PMRT: postmastectomy radiotherapy; NAC: neoadjuvant chemotherapy; SC: supraclavicular nodal region; AIs: aromatase inhibitors.